BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 24086951)

  • 1. Pomalidomide for patients with multiple myeloma.
    Gras J
    Drugs Today (Barc); 2013 Sep; 49(9):555-62. PubMed ID: 24086951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.
    Mark TM; Coleman M; Niesvizky R
    Leuk Res; 2014 May; 38(5):517-24. PubMed ID: 24690110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of pomalidomide therapy in multiple myeloma: a recent survey.
    Kumar A; Porwal M; Verma A; Mishra AK
    J Chemother; 2014 Dec; 26(6):321-7. PubMed ID: 25004945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pomalidomide: a review of its use in patients with recurrent multiple myeloma.
    Scott LJ
    Drugs; 2014 Apr; 74(5):549-62. PubMed ID: 24590685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
    Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
    Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pomalidomide: first global approval.
    Elkinson S; McCormack PL
    Drugs; 2013 May; 73(6):595-604. PubMed ID: 23572409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
    Lacy MQ; Tefferi A
    Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
    Highsmith KN; Chen SE; Horowitz S
    Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pomalidomide for the management of refractory multiple myeloma.
    Summers BB; Cole SW; Olin JL
    Am J Health Syst Pharm; 2014 Sep; 71(17):1443-8. PubMed ID: 25147167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pomalidomide in the management of relapsed multiple myeloma.
    Touzeau C; Moreau P
    Future Oncol; 2016 Sep; 12(17):1975-83. PubMed ID: 27283457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide in multiple myeloma.
    Richardson PG; Mitsiades C; Hideshima T; Anderson KC
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1165-73. PubMed ID: 16925483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pomalidomide. A last-line treatment option for multiple myeloma.
    Prescrire Int; 2014 Nov; 23(154):257-9. PubMed ID: 25954788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma.
    Hoy SM
    Drugs; 2017 Nov; 77(17):1897-1908. PubMed ID: 29110190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.
    Richardson PG; Mark TM; Lacy MQ
    Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S36-44. PubMed ID: 23786844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pomalidomide therapy for myeloma.
    Schey S; Ramasamy K
    Expert Opin Investig Drugs; 2011 May; 20(5):691-700. PubMed ID: 21413906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation.
    McCormack PL
    Drugs Aging; 2015 May; 32(5):409-18. PubMed ID: 25925941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
    Hanaizi Z; Flores B; Hemmings R; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
    Oncologist; 2015 Mar; 20(3):329-34. PubMed ID: 25673103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy.
    Leotta S; Pirosa MC; Markovic U; Scalise L; Bulla A; Sapienza G; Di Giorgio MA; Martino EA; Curto Pelle A; Leotta V; Milone G; Cupri A; Vaddinelli D; Villari L; Conticello C; Milone G
    Chemotherapy; 2019; 64(2):110-114. PubMed ID: 31533095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pomalidomide in the treatment of relapsed multiple myeloma.
    Forsberg PA; Mark TM
    Future Oncol; 2013 Jul; 9(7):939-48. PubMed ID: 23837756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pooled analysis of pomalidomide for treating patients with multiple myeloma.
    Sun JJ; Zhang C; Zhou J; Yang HL
    Asian Pac J Cancer Prev; 2015; 16(8):3163-6. PubMed ID: 25921115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.